Skip to main content
NFL Biosciences logo

NFL Biosciences — Investor Relations & Filings

Ticker · ALNFL ISIN · FR0014003XT0 LEI · 9695006VJWNTN4UNHA27 PA Professional, scientific and technical activities
Open in API
Filings indexed 182 across all filing types
Latest filing 2025-07-28 Regulatory Filings
Country FR France
Listing PA ALNFL

About NFL Biosciences

https://www.nflbiosciences.com/

NFL Biosciences is a biopharmaceutical company that develops botanical drug candidates for the treatment of addictions. The company's lead product, NFL-101, is a nicotine-free drug candidate for smoking cessation derived from a protein extract of tobacco leaves. Its development pipeline also includes NFL-301, a candidate aimed at reducing excessive alcohol consumption. NFL Biosciences focuses on advancing its products through clinical trials with the goal of licensing them to pharmaceutical companies for commercialization.

Recent filings

Filing Released Lang Actions
Inside Information / Other news releases
Regulatory Filings Classification · 95% confidence The document is a press release issued by NFL Biosciences announcing a new scientific collaboration with McLean Hospital to study the mechanism of action of their drug candidate, NFL-101. It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor is it a report publication announcement. As it is a general corporate announcement regarding business development and research activities, it falls under the 'Regulatory Filings' (RNS) category as the appropriate fallback for miscellaneous corporate news.
2025-07-28 English
Inside Information / Other news releases
Capital/Financing Update Classification · 98% confidence The document is a press release announcing that the company has secured €1.2 million in non-dilutive financing (bank loans and a repayable advance). This falls under the category of company fundraising and financing activities. It is not a report publication announcement, nor is it a capital change (like a share issue), but rather a financing update.
2025-07-22 English
Informations privilégiées / Autres communiqués
Capital/Financing Update Classification · 100% confidence The document is a press release announcing that the company has secured 1.2 million euros in non-dilutive financing through a combination of government innovation grants and bank loans. This falls under the category of company fundraising and financing activities. It is not a report publication announcement, but rather a direct announcement of a capital/financing event.
2025-07-22 French
NFL Biosciences strengthens its clinical leadership by expanding Dr. Yannick Plétan’s role as Chief Medical Officer as part of the acceleration of its clinical development program for NFL-101 in smoki
Board/Management Information Classification · 100% confidence The document is a press release announcing the expansion of Dr. Yannick Plétan's role as Chief Medical Officer at NFL Biosciences. This constitutes a change in senior management/leadership. According to the provided definitions, announcements regarding changes in senior management fall under the 'Board/Management Information' (MANG) category.
2025-07-03 English
NFL Biosciences annonce l’élargissement du rôle du Dr. Yannick Plétan par sa nomination en qualité de Directeur Médical dans le cadre de l’accélération de son programme de développement clinique de NF
Board/Management Information Classification · 100% confidence The document is a press release announcing the appointment of Dr. Yannick Plétan as the new Medical Director of NFL Biosciences. This falls under the category of management changes or board/senior leadership updates. According to the provided definitions, announcements regarding changes in senior management are classified as 'MANG'.
2025-07-03 French
Bilan semestriel du contrat de liquidité
Net Asset Value Classification · 95% confidence The document is a 'Bilan semestriel du contrat de liquidité' (Half-year report on the liquidity contract) for NFL Biosciences. It details the number of shares and cash held in the liquidity account as of June 30, 2025, and provides a table of daily trading activity (purchases and sales) for the first half of 2025. This type of disclosure is a standard regulatory requirement for companies listed on Euronext Growth Paris to report on their liquidity provider's activities. It does not fit into the categories of annual or interim financial reports, nor is it a simple announcement of a report; it is the report itself. Therefore, it is classified as a Regulatory Filing (RNS).
2025-07-02 French

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.